XBIvsBBPETF Comparison
VS
State Street SPDR S&P Biotech ETF (XBI) belongs to the US Health Care segment. Virtus LifeSci Biotech Products ETF (BBP) is part of the Tomorrow's Treatments segment. XBI's top 2 sector exposures are Healthcare and Finance. In contrast, BBP's top sector exposures are Healthcare. XBI is more expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.34% for BBP. XBI is up 30.8% year-to-date (YTD) with +$806M in YTD flows. BBP performs better with 33.51% YTD performance, and +$50M in YTD flows. Run a side-by-side ETF comparison of XBI and BBP below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XBI vs BBP performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/09/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI BBP | +0.84%+5.27% | +21.41%+26.69% | +30.80%+33.51% | +68.54%+51.93% | +103.54%+101.25% | +20.80%+103.38% |
| Flows | XBI BBP | +$372M+$5M | +$1.20B+$20M | +$806M+$50M | +$1.60B+$62M | -$130M+$68M | +$1.59B+$61M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI BBP | +29.80%+25.82% | +27.95%+25.10% | +28.29%+24.71% | +32.91%+26.60% |
| Max drawdown | XBI BBP | -10.46%-9.34% | -10.46%-9.59% | -32.94%-25.54% | -53.28%-37.61% |
| Max drawdown duration | XBI BBP | 40d39d | 40d48d | 331d292d | 1622d586d |
Trading data
XBI | BBP | |
Last sale 9/9/2026 at 1:30 PM | $159.38 | $105.52 |
| Previous close 09/09/2026 | $161.93 | $106.71 |
| Consolidated volume 09/09/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XBI | BBP | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/9/2026 at 1:30 PM
Live
Closed
XBI | BBP | |
|---|---|---|
| Last price | $159.38 | $105.52 |
| 1D performance | -1.57% | -1.12% |
| AuM | $11.00 B | $117.14 M |
| E/R | 0.35% | 0.34% |
Characteristics
XBI | BBP | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | VIRTUS Investment Partners |
| Benchmark | S&P Biotechnology Select Industry Index | LifeSci Biotechnology Products Index |
| N° of holdings | 149 | 66 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | December 16, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
XBI
USA
95.3%
Other
4.7%
BBP
USA
86.5%
Other
13.5%
Sectors
XBI
Healthcare
99.41%
Other
0.59%
BBP
Healthcare
98.2%
Other
1.8%
Diversification
XBI
Total weight of top 15 holdings out of 15
20.29%
BBP
Total weight of top 15 holdings out of 15
26.78%
Top 15 holdings
Data as of July 31, 2026
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
BBP
Crinetics Pharmaceuticals, Inc.
3.24%
Verastem, Inc.
1.98%
Nuvation Bio, Inc.
1.80%
Omeros Corp.
1.73%
Geron Corp.
1.72%
BridgeBio Pharma, Inc.
1.68%
Agios Pharmaceuticals, Inc.
1.67%
Protagonist Therapeutics, Inc.
1.65%
BeOne Medicines Ltd.
1.64%
Kiniksa Pharmaceuticals International Plc
1.63%
Precigen, Inc.
1.62%
Xeris Biopharma Holdings, Inc.
1.61%
ACADIA Pharmaceuticals, Inc.
1.60%
Iovance Biotherapeutics, Inc.
1.60%
Rhythm Pharmaceuticals, Inc.
1.60%
Frequently asked questions about XBI and BBP
How have the XBI and BBP ETFs performed in 2026?
As of September 9, 2026, XBI is up 30.8% year-to-date (YTD), while BBP has returned 33.51%. That puts BBP better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or BBP?
Year-to-date, the XBI ETF saw +$806M in flows, compared to +$50M for BBP.
Which ETF is more volatile: XBI or BBP?
Over the past year, XBI had a volatility of 27.95%, while BBP experienced 25.1%.
Which ETF is bigger: XBI or BBP?
As of September 9, 2026, XBI holds $11.00 B in assets under management (AUM), while BBP manages $117.14 M.
What sectors do the XBI and BBP ETFs invest in?
XBI leans toward sectors like Healthcare. Meanwhile, BBP focuses on Healthcare.
What are the top holdings of the XBI ETF and BBP ETF?
XBI top holdings include Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Dianthus Therapeutics, Inc.. BBP holds in its top three: Crinetics Pharmaceuticals, Inc., Verastem, Inc. and Nuvation Bio, Inc..
Which ETF is more diversified: XBI or BBP?
XBI holds 151 securities with 20.29% of its assets in the top 15. BBP has 66 securities and a top 15 weight of 26.78%.
Advertisement
Latest news about XBI & BBP
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
